Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.59 |
| ▸ | SCN1A | P35498 | 2/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | THPO | P40225 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956551 | 0.86 | SLC29A1 (0.64) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL9653043 | 0.86 | KMT2A (0.53) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| Ethyltrimethoxy Benzoate SCHEMBL4410910 | 0.84 | KMT2A (0.66) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL7952952 | 0.83 | SCN1A (0.68) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL7635612 | 0.83 | KMT2A (0.50) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL7956555 | 0.82 | SLC29A1 (0.67) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL10428055 | 0.82 | SLC29A1 (0.59) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL10887449 | 0.82 | SLC29A1 (0.59) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL10428390 | 0.82 | SLC29A1 (0.59) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 | |
| SCHEMBL9419914 | 0.81 | SLC29A1 (0.55) | SLC29A1SCN1ASCN2ASCN3ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119346-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | Chromatin Technologies | 2015-04-30 | — | — | US | disclosed |
| US-8921533-B2 | Glycosylated valproic acid analogs and uses thereof | Chromatin Technologies (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130029924-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | Chromatin Technologies (US) | 2013-01-31 | — | — | US | disclosed |
| US-6245779-B1 | ANALGESICS; ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0997463-A1 | NAPHTHYRIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0508549-B1 | New triazolopyrimidine and pyrazolopyrimidine derivatives useful for treating cachexia | SANKYO CO (JP) | 1995-04-26 | — | — | EP | disclosed |
| EP-0347252-B1 | METHOD OF TREATING CACHEXIA AND CERTAIN NEW COMPOUNDS FOR USE IN THIS METHOD | SANKYO COMPANY LIMITED (JP) | 1993-05-05 | — | — | EP | disclosed |
| US-5162573-A | Anticonvulsant, antiepileptic agent | CHIESI FARMACEUTICI S.P.A. (IT) | 1992-11-10 | — | — | US | disclosed |
| EP-0508549-A2 | New triazolopyrimidine and pyrazolopyrimidine derivatives useful for treating cachexia | SANKYO COMPANY LIMITED (JP) | 1992-10-14 | — | — | EP | disclosed |
| EP-0250997-B1 | VALPROIC AND (E)-2-VALPROENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM | CHIESI FARMACEUTICI S.p.A. (IT) | 1992-04-15 | — | — | EP | disclosed |
| US-5086057-A | METHOD OF TREATING CACHEXIA AND CERTAIN NEW COMPOUNDS FOR USE IN THIS METHOD | SANKYO COMPANY LIMITED (JP) | 1992-02-04 | — | — | US | disclosed |
| US-5055479-A | For enhancing activity of lipoprotein lipase enzymes | SANKYO COMPANY, LIMITED (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0250997-A2 | Valproic and (E)-2-valproenoic acid derivatives, processes for the preparation thereof and pharmaceutical compositions therefrom | CHIESI FARMACEUTICI S.p.A. (IT) | 1988-01-07 | — | — | EP | disclosed |
| US-3985881-A | 1(3,4,5-Trimethoxybenzamido methyl) tetrahydro isoquinoline derivatives and a process for their production | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029924-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | HDAC3, VGF, HDAC1 | SLC29A1 1507/4885SCN1A 474/4885SCN2A 315/4885 |
| US-20150119346-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | HDAC3, VGF, HDAC1 | SLC29A1 1507/4885SCN1A 474/4885SCN2A 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.